Karine Breckpot (°1976, https://orcid.org/0000-0003-4331-3480) obtained a MSc in Biomedical Sciences in 1998 and a PhD in Medical Sciences in 2004, all at the Vrije Universiteit Brussel (VUB, Belgium). Following a postdoctoral stay at the Division of Infection and Immunity at the University College London (United Kingdom), she became a group leader and Assistant Professor in 2010 at the Laboratory for Molecular and Cellular Therapy (LMCT), VUB. She became a Tenured Professor in 2014 and Full Professor in 2019. Since 2019 she is director of the research group LMCT (https://lmct.research.vub.be), focused on cancer immunology and immunotherapy, designing novel immunotherapies using technologies such as mRNA, lentiviral vectors and antibodies, including camelid single domain antibodies. She was laureate of the Fund for Biotechnology award in 2005, received the Dr. Karel-Lodewijk Verleysen award of the Belgian Royal Academy of Medicine in 2011, the Melanoma Research Alliance young investigator award in 2017 and the BCLAS award in honor of Jean-René Maisin in 2019. She is (co)promotor of 11 defended and 16 ongoing doctoral theses and author on >100 Q1 publications.